Imagine a tiny chip that works like a high-tech lab in your pocket. Instead of sending blood samples to a big hospital and waiting days, a simple finger prick tells doctors exactly which heart medication will work best for you. It uses AI to spot hidden patterns in your blood to prevent a second heart attack before it happens.
High-risk cardiovascular patients often suffer subsequent heart attacks because current diagnostics are either too basic or require expensive, centralized hospital equipment. This creates a gap in personalized, immediate treatment stratification.
An advanced point-of-care lab-on-a-chip tool and an AI-powered analysis system to measure blood biomarkers and genetic polymorphisms from finger-prick samples.
If you are a device manufacturer dealing with the high cost of centralized lab equipment — this project developed a microfluidic PoC tool that allows complex biomarker testing via finger prick. This shifts high-end diagnostics from university hospitals to low-threshold healthcare settings.
If you are a pharma company dealing with varying patient responses to heart medication — this project developed a companion diagnostic tool that stratifies patients. This ensures approved pharmaceuticals are prescribed to the right high-risk patients based on their specific biomarker patterns.
If you are an AI firm dealing with the need for high-quality clinical data for predictive modeling — this project developed an AI-powered computational analysis system. It uses data from a multinational trial to explore predictors for primary and secondary heart outcomes.
Based on available project data, the specific unit price or cost of the tool is not mentioned; however, the project is supported by an EU contribution of EUR 13,978,057.
The project utilizes lab-on-a-chip and microfluidic technology, which are typically scalable, and includes 2 SMEs in the consortium to support development.
Based on available project data, specific licensing terms are not listed, but the project aims to provide the scientific foundation for regulatory approval of companion diagnostics.
The project period runs from 2023-12-01 to 2028-11-30, suggesting a development and validation cycle ending in late 2028.
The tool is designed for point-of-care use via finger prick blood, allowing it to be used in low-threshold healthcare institutions rather than just tertiary university hospitals.
The consortium is heavily research-driven with 5 universities and 1 research institute, but maintains a 25% industry ratio through 2 SMEs. This balance suggests a strong academic foundation for biomarker discovery combined with the practical engineering capacity of SMEs to refine the lab-on-a-chip hardware across 8 different countries.
Contact the Medical University of Graz (AT)
Contact us to explore licensing opportunities for the PoCCardio microfluidic tool.
